Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CALT NASDAQ:ELVN NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.83+3.2%$4.12$2.90▼$11.16$327.43M-0.012.97 million shs2.74 million shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AELVNEnliven Therapeutics$20.27-0.4%$20.45$13.30▼$30.03$1.21B0.93419,198 shs589,226 shsPGENPrecigen$4.51-0.9%$2.16$0.65▼$4.82$1.34B1.8716.92 million shs9.09 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+3.23%+8.19%+4.93%-29.47%-40.90%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-1.23%ELVNEnliven Therapeutics-0.44%-2.78%+4.92%+13.62%-9.51%PGENPrecigen-0.88%+7.89%+160.69%+241.67%+299.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune3.262 of 5 stars4.33.00.00.02.41.70.6CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AELVNEnliven Therapeutics2.8056 of 5 stars3.52.00.00.02.74.20.0PGENPrecigen4.0753 of 5 stars3.40.00.04.73.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40354.31% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AELVNEnliven Therapeutics 3.00Buy$41.20103.26% UpsidePGENPrecigen 2.80Moderate Buy$8.2582.93% UpsideCurrent Analyst Ratings BreakdownLatest ALT, CALT, PGEN, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025PGENPrecigenCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/19/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.008/19/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.508/15/2025PGENPrecigenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.008/13/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,901.79N/AN/A$1.83 per share2.09CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74ELVNEnliven TherapeuticsN/AN/AN/AN/A$8.25 per shareN/APGENPrecigen$4.34M309.64N/AN/A($0.12) per share-37.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AELVNEnliven Therapeutics-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)PGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)Latest ALT, CALT, PGEN, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44CALTCalliditas Therapeutics AB (publ)9.442.692.59ELVNEnliven TherapeuticsN/A32.5832.58PGENPrecigenN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CALTCalliditas Therapeutics AB (publ)2.83%ELVNEnliven Therapeutics95.08%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%CALTCalliditas Therapeutics AB (publ)2.20%ELVNEnliven Therapeutics25.90%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionableALT, CALT, PGEN, and ELVN HeadlinesRecent News About These CompaniesNancy Agee Buys 15,360 Shares of Precigen (NASDAQ:PGEN) StockAugust 30 at 7:33 AM | insidertrades.comPrecigen (NASDAQ:PGEN) Hits New 12-Month High - Here's WhyAugust 29 at 11:13 AM | marketbeat.comPrecigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory PapillomatosisAugust 27 at 9:53 AM | finance.yahoo.comCitizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform RatingAugust 26, 2025 | insidermonkey.comH.C. Wainwright Remains Bullish on Precigen (PGEN)August 26, 2025 | finance.yahoo.comPGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease DrugAugust 25, 2025 | zacks.comPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. WainwrightAugust 25, 2025 | prnewswire.comAnalysts Set Precigen, Inc. (NASDAQ:PGEN) Target Price at $8.25August 24, 2025 | americanbankingnews.comPrecigen Inc. (PGEN) Stock Price Today - WSJAugust 22, 2025 | wsj.comCantor Fitzgerald Cuts Earnings Estimates for PrecigenAugust 22, 2025 | marketbeat.comPrecigen Target of Unusually High Options Trading (NASDAQ:PGEN)August 22, 2025 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Trading Up 10.9% After Analyst UpgradeAugust 21, 2025 | marketbeat.comPrecigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 21, 2025 | marketbeat.comPrecigen (PGEN) Gets a Buy from Cantor FitzgeraldAugust 21, 2025 | theglobeandmail.comPrecigen (NASDAQ:PGEN) Given New $8.00 Price Target at JMP SecuritiesAugust 21, 2025 | marketbeat.comPrecigen (NASDAQ:PGEN) Earns Buy Rating from HC WainwrightAugust 21, 2025 | marketbeat.comFY2026 EPS Estimates for Precigen Decreased by AnalystAugust 21, 2025 | americanbankingnews.comPrecigen files to sell 143.81M shares of common stock for holdersAugust 20, 2025 | msn.comPrecigen (NASDAQ:PGEN) Sees Large Volume Increase - Still a Buy?August 20, 2025 | marketbeat.comMill Creek Capital Advisors LLC Grows Stock Position in Precigen, Inc. $PGENAugust 20, 2025 | marketbeat.comPrecigen (NASDAQ:PGEN) Given Buy Rating at HC WainwrightAugust 20, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNHBy Ryan Hasson | August 15, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025ALT, CALT, PGEN, and ELVN Company DescriptionsAltimmune NASDAQ:ALT$3.83 +0.12 (+3.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.79 -0.04 (-1.15%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 08/29/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Enliven Therapeutics NASDAQ:ELVN$20.27 -0.09 (-0.44%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$20.27 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Precigen NASDAQ:PGEN$4.51 -0.04 (-0.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.62 +0.12 (+2.55%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
